JP2021511291A - 置換ピラゾロ[1,5−a]ピリミジン化合物並びにその医薬組成物および使用 - Google Patents
置換ピラゾロ[1,5−a]ピリミジン化合物並びにその医薬組成物および使用 Download PDFInfo
- Publication number
- JP2021511291A JP2021511291A JP2020534179A JP2020534179A JP2021511291A JP 2021511291 A JP2021511291 A JP 2021511291A JP 2020534179 A JP2020534179 A JP 2020534179A JP 2020534179 A JP2020534179 A JP 2020534179A JP 2021511291 A JP2021511291 A JP 2021511291A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- deuterium
- cancer
- mmol
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 191
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 51
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 229940002612 prodrug Drugs 0.000 claims abstract description 17
- 239000000651 prodrug Substances 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 229910052805 deuterium Inorganic materials 0.000 claims description 109
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 103
- 229910052739 hydrogen Inorganic materials 0.000 claims description 80
- 239000001257 hydrogen Substances 0.000 claims description 80
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 53
- 206010028980 Neoplasm Diseases 0.000 claims description 50
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 47
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 42
- 201000011510 cancer Diseases 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 17
- 208000002193 Pain Diseases 0.000 claims description 13
- 230000036407 pain Effects 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 101150111783 NTRK1 gene Proteins 0.000 claims description 9
- 101150056950 Ntrk2 gene Proteins 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 101150117329 NTRK3 gene Proteins 0.000 claims description 6
- 150000001975 deuterium Chemical group 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 3
- 208000024699 Chagas disease Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims 1
- -1 pyrimidine compound Chemical class 0.000 abstract description 57
- 239000000126 substance Substances 0.000 abstract description 5
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 71
- 239000000203 mixture Chemical class 0.000 description 70
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 46
- 230000015572 biosynthetic process Effects 0.000 description 40
- 238000003786 synthesis reaction Methods 0.000 description 39
- 239000000706 filtrate Substances 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 31
- 235000002639 sodium chloride Nutrition 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 0 *C(*)(C(*)(*)[C@]1(*)C(C=C(CC2)F)=C2F)C(*)(*)N1c(cc[n]1nc2)nc1c2NC(N(CC1)C[C@@]1O)=O Chemical compound *C(*)(C(*)(*)[C@]1(*)C(C=C(CC2)F)=C2F)C(*)(*)N1c(cc[n]1nc2)nc1c2NC(N(CC1)C[C@@]1O)=O 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- 239000000843 powder Substances 0.000 description 22
- 238000004440 column chromatography Methods 0.000 description 21
- 150000002431 hydrogen Chemical class 0.000 description 21
- 229940124597 therapeutic agent Drugs 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 239000008346 aqueous phase Substances 0.000 description 16
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 108010025020 Nerve Growth Factor Proteins 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000004698 Polyethylene Substances 0.000 description 11
- 125000004431 deuterium atom Chemical group 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 210000001853 liver microsome Anatomy 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 229950003970 larotrectinib Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- VYEUPRYCLWAOMU-UHFFFAOYSA-N 5-chloro-3-nitropyrazolo[1,5-a]pyrimidine Chemical compound C1=CC(Cl)=NC2=C([N+](=O)[O-])C=NN21 VYEUPRYCLWAOMU-UHFFFAOYSA-N 0.000 description 7
- 206010018338 Glioma Diseases 0.000 description 7
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 7
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 7
- 102000007072 Nerve Growth Factors Human genes 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000003900 neurotrophic factor Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- YWFPGZXICYWLAP-RRVWJQJTSA-N [2H]C1(CC(C(N1C(=O)N)([2H])[2H])O)[2H] Chemical compound [2H]C1(CC(C(N1C(=O)N)([2H])[2H])O)[2H] YWFPGZXICYWLAP-RRVWJQJTSA-N 0.000 description 6
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 5
- YWFPGZXICYWLAP-UHFFFAOYSA-N 3-hydroxypyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCC(O)C1 YWFPGZXICYWLAP-UHFFFAOYSA-N 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 229940125773 compound 10 Drugs 0.000 description 5
- 229940125797 compound 12 Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- 229940053128 nerve growth factor Drugs 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- NYNZQNWKBKUAII-YRYATMCWSA-N (3S)-2,2,5,5-tetradeuterio-N-[5-[(5R)-2,2-dideuterio-5-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(C(CC1)([2H])[2H])C1=NC=2N(C=C1)N=CC=2NC(=O)N1C([C@H](CC1([2H])[2H])O)([2H])[2H] NYNZQNWKBKUAII-YRYATMCWSA-N 0.000 description 4
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 4
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 4
- XCRCSPKQEDMVBO-UHFFFAOYSA-N 2-bromo-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(Br)=C1 XCRCSPKQEDMVBO-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ZVNXKHRULOZLHG-UHFFFAOYSA-N 5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-nitropyrazolo[1,5-a]pyrimidine Chemical compound N=1C2=C([N+](=O)[O-])C=NN2C=CC=1N1CCCC1C1=CC(F)=CC=C1F ZVNXKHRULOZLHG-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229940125851 compound 27 Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 238000004237 preparative chromatography Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 229940126639 Compound 33 Drugs 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 3
- 206010027452 Metastases to bone Diseases 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000223109 Trypanosoma cruzi Species 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960001292 cabozantinib Drugs 0.000 description 3
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 210000004500 stellate cell Anatomy 0.000 description 3
- 238000009495 sugar coating Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 108010064884 trkA Receptor Proteins 0.000 description 3
- 102000015533 trkA Receptor Human genes 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 2
- NCXSNNVYILYEBC-UHFFFAOYSA-N 2-(2,5-difluorophenyl)pyrrolidine Chemical compound FC1=CC=C(F)C(C2NCCC2)=C1 NCXSNNVYILYEBC-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- PNTNLXBVYHOZQI-UHFFFAOYSA-N 5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-amine Chemical compound N=1C2=C(N)C=NN2C=CC=1N1CCCC1C1=CC(F)=CC=C1F PNTNLXBVYHOZQI-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010023256 Juvenile melanoma benign Diseases 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010045515 Undifferentiated sarcoma Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 208000030173 low grade glioma Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229960005562 radium-223 Drugs 0.000 description 2
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 229960004836 regorafenib Drugs 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 108010064892 trkC Receptor Proteins 0.000 description 2
- 102000047459 trkC Receptor Human genes 0.000 description 2
- 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- NXNQLECPAXXYTR-LCYFTJDESA-N (3z)-3-[(1-methylindol-3-yl)methylidene]-1h-pyrrolo[3,2-b]pyridin-2-one Chemical compound C12=CC=CC=C2N(C)C=C1\C=C/1C2=NC=CC=C2NC\1=O NXNQLECPAXXYTR-LCYFTJDESA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- WLAVZAAODLTUSW-UHFFFAOYSA-N 1-n'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=O)C4(CC4)C(=O)NC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 WLAVZAAODLTUSW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NCXSNNVYILYEBC-UMPXIDFVSA-N 2,2,3-trideuterio-5-(2,5-difluorophenyl)pyrrolidine Chemical compound FC1=C(C=C(C=C1)F)C1CC(C(N1)([2H])[2H])[2H] NCXSNNVYILYEBC-UMPXIDFVSA-N 0.000 description 1
- QIZHVCUPPAMGIW-BFWBPSQCSA-N 2,2-dideuterio-5-(2,5-difluorophenyl)-3,4-dihydropyrrole Chemical compound FC1=C(C=C(C=C1)F)C=1CCC(N=1)([2H])[2H] QIZHVCUPPAMGIW-BFWBPSQCSA-N 0.000 description 1
- NCXSNNVYILYEBC-JNVXYVGESA-N 2,3,3,5,5-pentadeuterio-2-(2,5-difluorophenyl)pyrrolidine Chemical compound FC1=C(C=C(C=C1)F)C1(NC(CC1([2H])[2H])([2H])[2H])[2H] NCXSNNVYILYEBC-JNVXYVGESA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FFRUQSUMDFNBLG-UHFFFAOYSA-N 2-(2,4,5-trichlorophenoxy)ethyl 2,2,2-trichloroacetate Chemical compound ClC1=CC(Cl)=C(OCCOC(=O)C(Cl)(Cl)Cl)C=C1Cl FFRUQSUMDFNBLG-UHFFFAOYSA-N 0.000 description 1
- DOMVYDBGOVLUEL-UHFFFAOYSA-N 2-hydroxypyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1O DOMVYDBGOVLUEL-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- CGNJNFZTDWGNSF-UHFFFAOYSA-N 2h-pyrimidin-1-amine Chemical compound NN1CN=CC=C1 CGNJNFZTDWGNSF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- NCXSNNVYILYEBC-DICFDUPASA-N 4,4-dideuterio-2-(2,5-difluorophenyl)pyrrolidine Chemical compound FC1=C(C=C(C=C1)F)C1NCC(C1)([2H])[2H] NCXSNNVYILYEBC-DICFDUPASA-N 0.000 description 1
- WSTUJEXAPHIEIM-UHFFFAOYSA-N 4-fluoro-n-[6-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-1-[4-(propan-2-ylcarbamoyl)cyclohexyl]benzimidazol-2-yl]benzamide Chemical compound C1CC(C(=O)NC(C)C)CCC1N(C=1C(=CC=C(CN2CCC(CC2)C(C)(C)O)C=1)N\1)C/1=N/C(=O)C1=CC=C(F)C=C1 WSTUJEXAPHIEIM-UHFFFAOYSA-N 0.000 description 1
- LBVKEEFIPBQIMD-JTQLQIEISA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyridin-2-yl)ethyl]-4-n-(3-propan-2-yloxy-1h-pyrazol-5-yl)pyrimidine-2,4-diamine Chemical compound N1C(OC(C)C)=CC(NC=2C(=CN=C(N[C@@H](C)C=3N=CC(F)=CC=3)N=2)Cl)=N1 LBVKEEFIPBQIMD-JTQLQIEISA-N 0.000 description 1
- YLLPAAYZOKXPDB-UHFFFAOYSA-N 5-pyrimidin-2-yl-1h-pyrazol-4-amine Chemical compound NC1=CNN=C1C1=NC=CC=N1 YLLPAAYZOKXPDB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- QUXRUQHCVUUDHV-UHFFFAOYSA-N CC(C)(C)OC(NCCCC(c1cc(F)ccc1F)=O)=O Chemical compound CC(C)(C)OC(NCCCC(c1cc(F)ccc1F)=O)=O QUXRUQHCVUUDHV-UHFFFAOYSA-N 0.000 description 1
- CXUFYNZKPWWWKU-JTQLQIEISA-N CO[C@@H](CC(N1Cc2ccccc2)=O)C1=O Chemical compound CO[C@@H](CC(N1Cc2ccccc2)=O)C1=O CXUFYNZKPWWWKU-JTQLQIEISA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- SFLAFDJPHSHJBI-UHFFFAOYSA-N Cc1n[n](ccc(N(CCC2)C2c(cc(cc2)F)c2F)n2)c2c1[N+]([O-])=O Chemical compound Cc1n[n](ccc(N(CCC2)C2c(cc(cc2)F)c2F)n2)c2c1[N+]([O-])=O SFLAFDJPHSHJBI-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- NCXSNNVYILYEBC-KAFRBFAESA-N FC1=C(C=C(C=C1)F)C1(NCCC1([2H])[2H])[2H] Chemical compound FC1=C(C=C(C=C1)F)C1(NCCC1([2H])[2H])[2H] NCXSNNVYILYEBC-KAFRBFAESA-N 0.000 description 1
- NYNZQNWKBKUAII-MLEBOOBGSA-N FC1=C(C=C(C=C1)F)C1N(CCC1)C1=NC=2N(C=C1)N=CC=2NC(=O)N1C([C@H](CC1([2H])[2H])O)([2H])[2H] Chemical compound FC1=C(C=C(C=C1)F)C1N(CCC1)C1=NC=2N(C=C1)N=CC=2NC(=O)N1C([C@H](CC1([2H])[2H])O)([2H])[2H] NYNZQNWKBKUAII-MLEBOOBGSA-N 0.000 description 1
- NCXSNNVYILYEBC-BFWBPSQCSA-N FC1=C(C=C(C=C1)F)C1NC(CC1)([2H])[2H] Chemical compound FC1=C(C=C(C=C1)F)C1NC(CC1)([2H])[2H] NCXSNNVYILYEBC-BFWBPSQCSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 230000037364 MAPK/ERK pathway Effects 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 description 1
- HNJBEVLQSNELDL-SMZGMGDZSA-N N1C(CCC1([2H])[2H])=O Chemical compound N1C(CCC1([2H])[2H])=O HNJBEVLQSNELDL-SMZGMGDZSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- DGVCEXQFNYYRQI-BTJKTKAUSA-N OC(=O)\C=C/C(O)=O.CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 Chemical compound OC(=O)\C=C/C(O)=O.CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 DGVCEXQFNYYRQI-BTJKTKAUSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- ZVNXKHRULOZLHG-DICFDUPASA-N [2H]C1([2H])CC(N(C1)C1=NC2=C(C=NN2C=C1)[N+]([O-])=O)C1=CC(F)=CC=C1F Chemical compound [2H]C1([2H])CC(N(C1)C1=NC2=C(C=NN2C=C1)[N+]([O-])=O)C1=CC(F)=CC=C1F ZVNXKHRULOZLHG-DICFDUPASA-N 0.000 description 1
- PNTNLXBVYHOZQI-DICFDUPASA-N [2H]C1([2H])CC(N(C1)C1=NC2=C(N)C=NN2C=C1)C1=CC(F)=CC=C1F Chemical compound [2H]C1([2H])CC(N(C1)C1=NC2=C(N)C=NN2C=C1)C1=CC(F)=CC=C1F PNTNLXBVYHOZQI-DICFDUPASA-N 0.000 description 1
- ZVNXKHRULOZLHG-QRHRGWFLSA-N [2H]C1([2H])CC([2H])([2H])C([2H])(N1C1=NC2=C(C=NN2C=C1)[N+]([O-])=O)C1=CC(F)=CC=C1F Chemical compound [2H]C1([2H])CC([2H])([2H])C([2H])(N1C1=NC2=C(C=NN2C=C1)[N+]([O-])=O)C1=CC(F)=CC=C1F ZVNXKHRULOZLHG-QRHRGWFLSA-N 0.000 description 1
- PNTNLXBVYHOZQI-SUIAVDRFSA-N [2H]C1([2H])CC([2H])([2H])C([2H])(N1C1=NC2=C(N)C=NN2C=C1)C1=CC(F)=CC=C1F Chemical compound [2H]C1([2H])CC([2H])([2H])C([2H])(N1C1=NC2=C(N)C=NN2C=C1)C1=CC(F)=CC=C1F PNTNLXBVYHOZQI-SUIAVDRFSA-N 0.000 description 1
- ZVNXKHRULOZLHG-NCYHJHSESA-N [2H]C1([2H])CCC(N1C1=NC2=C(C=NN2C=C1)[N+]([O-])=O)C1=CC(F)=CC=C1F Chemical compound [2H]C1([2H])CCC(N1C1=NC2=C(C=NN2C=C1)[N+]([O-])=O)C1=CC(F)=CC=C1F ZVNXKHRULOZLHG-NCYHJHSESA-N 0.000 description 1
- PNTNLXBVYHOZQI-NCYHJHSESA-N [2H]C1([2H])CCC(N1C1=NC2=C(N)C=NN2C=C1)C1=CC(F)=CC=C1F Chemical compound [2H]C1([2H])CCC(N1C1=NC2=C(N)C=NN2C=C1)C1=CC(F)=CC=C1F PNTNLXBVYHOZQI-NCYHJHSESA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- NKCVNYJQLIWBHK-UHFFFAOYSA-N carbonodiperoxoic acid Chemical compound OOC(=O)OO NKCVNYJQLIWBHK-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- NMMGUHANGUWNBN-OGLOGDKOSA-N cep-751 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1C[C@](OC)(CO)[C@]4(C)O1 NMMGUHANGUWNBN-OGLOGDKOSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XRZYELWZLNAXGE-KPKJPENVSA-N chembl539947 Chemical compound CC(C)(C)C1=CC(\C=C(/C#N)C(N)=S)=CC(C(C)(C)C)=C1O XRZYELWZLNAXGE-KPKJPENVSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- PSHRANCNVXNITH-UHFFFAOYSA-N dimethylamino acetate Chemical compound CN(C)OC(C)=O PSHRANCNVXNITH-UHFFFAOYSA-N 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229950000521 entrectinib Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000019382 nerve compression syndrome Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008039 phosphoramides Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000765 processed proteins & peptides Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940121610 selpercatinib Drugs 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229950010611 sitravatinib Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- GJJYYMXBCYYXPQ-NCYHJHSESA-N tert-butyl 2,2-dideuterio-5-oxopyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C(CCC1([2H])[2H])=O GJJYYMXBCYYXPQ-NCYHJHSESA-N 0.000 description 1
- GJJYYMXBCYYXPQ-UHFFFAOYSA-N tert-butyl 2-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1=O GJJYYMXBCYYXPQ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940126496 utatrectinib Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、X1、X2、X3、X4、X5およびX6はそれぞれ独立して水素または重水素であり、
付加的な条件は、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、X1、X2、X3、X4、X5およびX6の少なくとも1つが重水素化されているものまたは重水素であることである。
本明細書において、「重水素化」とは、特に断りのない限り、化合物または基のうちの1つ以上の水素が重水素で置換されていることを意味します。重水素化は、一置換、二置換、多置換、または全置換であり得る。「1つ以上の重水素化」という用語は、「1回以上の重水素化」と互換的に使用される。
本発明は、式(I)の置換ピラゾロ[1,5−a]ピリミジン化合物、またはその薬学的に許容される塩、プロドラッグ、水和物または溶媒化合物、結晶多形、立体異性体または同位体変異体を提供する。
R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、X1、X2、X3、X4、X5およびX6はそれぞれ独立して水素または重水素であり、
付加的な条件は、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、X1、X2、X3、X4、X5およびX6の少なくとも1つが重水素化されているものまたは重水素であることである。
R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13およびR14は、それぞれ独立して、水素または重水素から選択され、
付加的な条件は、上記の化合物が少なくとも1つの重水素原子を含むことである。
別の側面において、本発明は、本発明の化合物(「活性成分」とも呼ばれる)および薬学的に許容される賦形剤を含む医薬組成物を提供する。いくつかの実施形態では、前記医薬組成物は有効量の活性成分を含む。いくつかの実施形態では、前記医薬組成物は治療的有効量の活性成分を含む。いくつかの実施形態では、前記医薬組成物は予防的有効量の活性成分を含む。
本発明の化合物は、Trkファミリータンパク質チロシンキナーゼ阻害効果を示し、この化合物は、痛み、炎症、癌および特定の感染症を治療するために使用することができる。
2,5−ジフルオロブロモベンゼン(7.95g、41.4mmol)を無水THF(50mL)に溶解し、イソプロピルマグネシウムクロリドの無水THF溶液(31.1mL、62.2mmol)31.1mLを−45℃でゆっくりと滴下し、滴下終了後、0℃に自然昇温し1時間撹拌してから、−15℃で、N−tert−ブトキシカルボニル−2−ピロリドン(11.5g、62.1mmol)の無水テトラヒドロフラン(30mL)をゆっくりと滴下し、滴下終了後、室温で30分間攪拌した。反応液を飽和塩化アンモニウム溶液100mLに注ぎ10分間攪拌した後、静置分取し、水相を酢酸エチル30mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥した。ろ過濃縮し、カラムクロマトグラフィーにより、無色の固体として7.87g(収率:63.6%)の化合物1を得た。
LC−MS(APCI):m/z=300.0(M+1)+
化合物1(500mg、1.67mmol)をジクロロメタン(4.0mL)に溶解し、トリフルオロ酢酸(2.0mL)を室温でゆっくりと滴下して、滴下終了後、室温で1時間撹拌した。反応液を濃縮し、褐色の油状液として466mgの化合物2を得、精製せずにそのまま次のステップに用いた。
化合物2(466mg、1.67mmol)を無水メタノール(10mL)に溶解し、Pd/C(50mg)を加え、そして室温で一晩水素化した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を濃縮することにより、無色の油状物として305mgの化合物3を得、2つのステップでの収率は99%であった。
LC−MS(APCI):m/z=184.1(M+1)+
化合物3(500mg、2.73mmol)および5−クロロ−3−ニトロピラゾロ[1,5−a]ピリミジン(542mg、2.73mmol)を室温で無水エタノール(10mL)に溶解し、室温でDIPEA(1.76g、13.62mmol)を加え、30分間加熱還流した。反応液を濃縮し、カラムクロマトグラフィー(PE/EA、30%〜50%)により、淡黄色の固形粉末として781mg(収率:82.9%)の化合物4を得た。
LC−MS(APCI):m/z=346.5(M+1)+
化合物4(300mg、0.87mmol)を無水メタノール10mLと水3mLに溶解し、還元鉄粉(485mg、8.67mmol)と塩化アンモニウム(93mg、1.75mmol)を室温で加え、2時間加熱還流した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を約3mLまで濃縮し、酢酸エチル10mLおよび水5mLを加え、分取し、水相を酢酸エチル5mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮して、褐色の油状液として266mgの化合物5を得、これをそのまま次のステップに用いた。
L−リンゴ酸(10.0g、74.6mmol)とベンジルアミン(9.59g、89.5mmol)をキシレン250mLに分散させ、8時間加熱還流した。室温に冷却した後、温度を0℃に下げ、0℃で2時間撹拌した。ろ過し、フィルターケーキを石油エーテル200mLで洗浄し、フィルターケーキを収集し、カラムクロマトグラフィー(PE/EA:50%〜66%)により、白色の固形粉末として9.66gの化合物6を得た。
1H−NMR(300 MHz、CDCl3)δ 7.50〜7.14(m、5H)、4.67(t、J=1.2Hz、2H)、4.63(dd、J=5.8、2.5Hz、1H)、3.08(dd、J=18.2、8.4Hz、1H)、2.70(dd、J=18.2、4.8Hz、1H)
重水素化リチウムアルミニウム(LiAlD4、2.45g、58.3mmol)を無水テトラヒドロフラン70mLに分散させ、化合物6(3.0g、14.6mmol)のテトラヒドロフラン(70mL)溶液を−15℃でゆっくりと滴下し、滴下終了後、室温で一晩撹拌した。少量の硫酸ナトリウム十水和物を加えてクエンチし、反応液をろ過し、濾渣を酢酸エチル100mLで洗浄し、ろ液を濃縮し、無色の油状液として1.26gの化合物7を得、これをそのまま次のステップに用いた。
化合物7(526mg、2.9mmol)を重水素化メタノール10mLに溶解し、50℃で一晩水素化した。ろ過し、濾渣を酢酸エチル30mLで洗浄し、ろ液を濃縮し、褐色の油状液として255mgの化合物8を得、これをそのまま次のステップに用いた。
化合物5(270mg、0.86mmol)をジクロロメタン25mLに溶解し、CDI(N,N’−カルボニルジイミダゾール、283mg、1.74mmol)を室温で一度に加え、室温で2時間撹拌した。化合物8(160mg、1.75mmol)を一度に加え、室温で30分間攪拌した。水20mLを加え、室温で10分間攪拌した。分取し、水相をジクロロメタン20mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮し、カラムクロマトグラフィー(DCM/MeOH、0%〜10%)により、淡黄色の固形粉末として355mg(収率:95.4%)の化合物9を得た。
LC−MS(APCI):m/z=433.3(M+1)+
1H NMR(500 MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3.88(d、J=7.8Hz、1H)、3.70(d、J=7.9Hz、1H)、2.46(td、J=9.5、8.6、4.3Hz、1H)、2.11−1.98(m、6H)
キラル分取クロマトグラフィー用カラムを使用して、ラセミ化合物9を分離し、目的生成物L−1を得た。
LC−MS(APCI):m/z=433.3(M+1)+
1H NMR(500 MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3.88(d、J=7.8Hz、1H)、3.70(d、J=7.9Hz、1H)、2.46(td、J=9.5、8.6、4.3Hz、1H)、2.11−1.98(m、6H)
化合物2(500mg、1.79mmol)を重水素化メタノール10mLに溶解し、Pd/C(50mg)を加えて重水素加圧、室温で一晩水素化した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を濃縮し、無色の油状液として477mg(収率:95.4%)の化合物10を得た。
LC−MS(APCI):m/z=187.1(M+1)+
化合物10(500mg、2.7mmol)および5−クロロ−3−ニトロピラゾロ[1,5−a]ピリミジン(533mg、2.7mmol)を無水エタノール10mLに溶解し、DIPEA(1.74g、13.4mmol)を室温で加え、30分間加熱還流した。反応液を濃縮し、カラムクロマトグラフィー(PE/EA、30%〜50%)により、淡黄色の固形粉末として79mg(収率:84.4%)の化合物11を得た。
LC−MS(APCI):m/z=349.6(M+1)+
化合物11(300mg、0.86mmol)を無水メタノール10mLと水3mLに溶解し、還元鉄粉(485mg、8.66mmol)と塩化アンモニウム(93mg、1.75mmol)を室温で加え、2時間加熱還流した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を約3mLまで濃縮し、酢酸エチル10mLと水5mLを加え、分取し、水相を酢酸エチル5mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮して、褐色の油状液として273mgの化合物12を得、これをそのまま次のステップに用いた。
化合物12(273mg、0.86mmol)をジクロロメタン25mLに溶解し、CDI(282mg、1.74mmol)を室温で一度に加え、室温で2時間撹拌した。(S)−3−ピロリジノール(159mg、1.83mmol)を一度に加え、室温で30分間攪拌した。水20mLを加え、室温で10分間攪拌した。分取し、水相をジクロロメタン20mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮し、カラムクロマトグラフィー(DCM/MeOH、0%〜10%)により、淡黄色の固形粉末として320mg(収率:86.3%)の化合物13を得た。
LC−MS(APCI):m/z=432.2(M+1)+
1H NMR(500MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3.88(d、J=7.8Hz、1H)、3.70(d、J=7.9Hz、1H)、3.65〜3.44(m、3H)、2.11〜1.98(m、5H)
キラル分取クロマトグラフィー用カラムを使用して、ラセミ化合物13を分離し、目的生成物L−2を得た。
LC−MS(APCI):m/z=432.2(M+1)+
1H NMR(500 MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3.88(d、J=7.8Hz、1H)、3.70(d、J=7.9Hz、1H)、3.65〜3.44(m、3H)、2.11〜1.98(m、5H)
化合物12(270mg、0.85mmol)をジクロロメタン25mLに溶解し、CDI(282mg、1.74mmol)を室温で一度に加え、室温で2時間撹拌した。化合物8(159mg、1.74mmol)を一度に加え、室温で30分間撹拌した。水20mLを加え、室温で10分間攪拌した。分取し、水相をジクロロメタン20mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮し、カラムクロマトグラフィー(DCM/MeOH、0%〜10%)により、淡黄色の固形粉末として339mg(収率:91.8%)の化合物14を得た。
LC−MS(APCI):m/z=436.3(M+1)+
1H NMR(500 MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3.88(d、J=7.8Hz、1H)、3.70(d、J=7.9Hz、1H)、2.11〜1.98(m、4H)
キラル分取クロマトグラフィー用カラムを使用して、ラセミ化合物14を分離し、目的生成物L−3を得た。
LC−MS(APCI):m/z=436.3(M+1)+
1H NMR(500 MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3.88(d、J=7.8Hz、1H)、3.70(d、J=7.9Hz、1H)、2.11〜1.98(m、4H)
スクシンイミド(9.0g、90.9mmol)を重水素化メタノール60mLに溶解し、炭酸カリウム(1.44g、10.4mmol)を加え、マイクロ波加熱し120℃で30分間撹拌した。反応液を濃縮し、得られた固体は化合物15であり、これをそのまま次のステップに用いた。
上記のステップで得られた固体を無水テトラヒドロフラン400mLに分散させ、氷浴で水素化アルミニウムリチウム(LAH、3.05g、80.3mmol)を少しずつ加えた後、氷浴で15分間撹拌した。反応液を硫酸ナトリウム十水和物でクエンチし、ろ過し、濾渣を酢酸エチル200mLで洗浄し、ろ液を合わせて濃縮し、カラムクロマトグラフィー(PE/EA、25%〜50%)により、無色の油状液として1.44gの化合物16を得、これをそのまま次のステップの反応に供した。
化合物16(1.44g、16.2mmol)をジクロロメタン20mLに溶解し、室温でDIPEAとDMAPを加え、氷浴でBoc2Oをゆっくりと滴下し、滴下終了後、室温で一晩攪拌した。反応液を濃縮し、カラムクロマトグラフィーにより、褐色の油状液として586mgの化合物17を得、これを次のステップに供した。
2,5−ジフルオロブロモベンゼン(500mg、2.6mmol)をTHF 5mLに溶解し、イソプロピルマグネシウムクロリドの無水THF溶液(1.56mL、3.12mmol)を−45℃でゆっくりと滴下し、滴下終了後、0℃に自然昇温し1時間撹拌してから、化合物17(466mg、2.46mmol)のテトラヒドロフラン(5mL)溶液を−15℃でゆっくりと滴下し、滴下終了後、室温で30分間撹拌した。反応液を飽和塩化アンモニウム溶液10mLに注ぎ10分間攪拌し、静置分取し、水相を酢酸エチル10mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥した。ろ過濃縮し、カラムクロマトグラフィー(PE/EA、0%〜10%)により、無色の固体として367mg(収率:46.6%)の化合物18を得た。
化合物18(367mg、1.21mmol)をジクロロメタン4.0mLに溶解し、トリフルオロ酢酸2.0mLを室温でゆっくりと滴下し、滴下終了後、室温で1時間撹拌した。反応液を濃縮し、褐色の油状物として301mgの化合物19を得た。
化合物19(301mg、1.06mmol)を無水メタノール10mLに溶解し、Pd/C(30mg)を加え、室温で一晩水素化した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を濃縮し、無色の油状物として301mgの化合物20を得た。
LC−MS(APCI):m/z=186.3(M+1)+
化合物20(301mg、1.63mmol)および5−クロロ−3−ニトロピラゾロ[1,5−a]ピリミジン(300mg、1.51mmol)を無水エタノール10mLに溶解し、DIPEA(391mg、3.02mmol)を室温で加え、30分間加熱還流した。反応液を濃縮し、カラムクロマトグラフィー(PE/EA、30%〜50%)により、淡黄色の固形粉末として222mgの化合物21を得た。
LC−MS(APCI):m/z=348.3(M+1)+
化合物21(222mg、0.64mmol)を無水メタノール10mLと水3mLに溶解し、還元鉄粉(357mg、6.37mmol)と塩化アンモニウム(68mg、1.28mmol)を室温で加え、2時間加熱還流した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を約3mLまで濃縮し、酢酸エチル10mLおよび水5mLを加え、分取し、水相を酢酸エチル5mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮して、褐色の油状液として195mgの化合物22を得、これをそのまま次のステップに用いた。
化合物22(195mg、0.61mmol)をジクロロメタン25mLに溶解し、CDI(199mg、1.23mmol)を室温で一度に加え、室温で2時間撹拌した。(S)−3−ピロリジノール(107mg、1.23mmol)を一度に加え、室温で30分間攪拌した。水20mLを加え、室温で10分間攪拌した。分取し、水相をジクロロメタン20mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮し、カラムクロマトグラフィー(DCM/MeOH、0%〜10%)により、淡黄色の固形粉末として102mg(収率:38.9%)の化合物23を得た。
LC−MS(APCI):m/z=431.2(M+1)+
1H NMR(500MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3.88(d、J=7.8Hz、1H)、3.70(d、J=7.9Hz、1H)、3.65〜3.44(m、4H)、2.46(td、J=9.5、8.6、4.3Hz、1H)、2.11〜1.98(m、4H)
キラル分取クロマトグラフィー用カラムを使用して、ラセミ化合物23を分離し、目的生成物L−4を得た。
LC−MS(APCI):m/z=431.2(M+1)+
1H NMR(500MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3.88(d、J=7.8Hz、1H)、3.70(d、J=7.9Hz、1H)、3.65〜3.44(m、4H)、2.46(td、J=9.5、8.6、4.3Hz、1H)、2.11〜1.98(m、4H)
スクシンイミド(3.0g、30.3mmol)を無水テトラヒドロフラン130mLに分散させ、氷浴でLiAlD4(1.02g、24.3mmol)を少しずつ加えた後、氷浴で15分間撹拌した。反応液を硫酸ナトリウム十水和物でクエンチし、ろ過し、濾渣を酢酸エチル70mLで洗浄し、ろ液を合わせて濃縮し、カラムクロマトグラフィー(PE/EA、25%〜50%)により、無色の油状液として1.44gの化合物24を得、これをそのまま次のステップに供した。
化合物24(1.44g、16.5mmol)をジクロロメタン20mLに溶解し、DIPEA(8.55g、66.1mmol)およびDMAP(404mg、3.3mmol)を室温で加え、氷浴でBoc2O(7.22g、33.1mmol)をゆっくりと滴下し、滴下終了後、室温で一晩撹拌した。反応液を濃縮し、カラムクロマトグラフィーにより、褐色の油状液として586mgの化合物25を得、これをそのまま次のステップに供した。
2,5−ジフルオロブロモベンゼン(500mg、2.6mmol)をTHF 5mLに溶解し、イソプロピルマグネシウムクロリドの無水THF溶液(1.55mL、3.1mmol)を−45℃でゆっくりと滴下し、滴下終了後、0℃に自然昇温し1時間撹拌してから、化合物25(466mg、2.49mmol)のテトラヒドロフラン(5mL)溶液を−15℃でゆっくりと滴下し、滴下終了後、室温で30分間攪拌した。反応液を飽和塩化アンモニウム溶液10mLに注ぎ10分間攪拌し、静置分取し、水相を酢酸エチル10mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥した。ろ過濃縮し、カラムクロマトグラフィー(PE/EA、0%〜10%)により、無色の固体として380mgの化合物26を得た。
化合物26(380mg、1.26mmol)をジクロロメタン4.0mLに溶解し、トリフルオロ酢酸2.0mLを室温でゆっくりと滴下し、滴下終了後、室温で1時間撹拌した。反応液を濃縮し、褐色の油状液として339mgの化合物27を得た。
化合物27(339mg、1.21mmol)を無水メタノール10mLに溶解し、Pd/C(30mg)を加え、室温で一晩水素化した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を濃縮し、無色の油状液として313mgの化合物28を得た。
LC−MS(APCI):m/z=186.1(M+1)+
化合物28(313mg、1.69mmol)および5−クロロ−3−ニトロピラゾロ[1,5−a]ピリミジン(335mg、1.69mmol)を無水エタノール10mLに溶解し、DIPEA(391mg、3.02mmol)を室温で加え、30分間加熱還流した。反応液を濃縮し、カラムクロマトグラフィー(PE/EA、30%〜50%)により、淡黄色の固形粉末として320mgの化合物29を得た。
LC−MS(APCI):m/z=348.5(M+1)+
化合物29(300mg、0.86mmol)を無水メタノール10mLと水3mLに溶解し、還元鉄粉(485mg、8.6mmol)と塩化アンモニウム(93mg、1.75mmol)を室温で加え、2時間加熱還流した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を約3mLまで濃縮し、酢酸エチル10mLおよび水5mLを加え、分取し、水相を酢酸エチル5mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮して、褐色の油状液として251mgの化合物30を得、これをそのまま次のステップに用いた。
化合物30(150mg、0.47mmol)をジクロロメタン15mLに溶解し、CDI(92mg、0.57mmol)を室温で一度に加え、室温で2時間撹拌した。(S)−3−ピロリジノール(62mg、0.71mmol)を一度に加え、室温で30分間攪拌した。水10mLを加え、室温で10分間攪拌した。分取し、水相をジクロロメタン10mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮し、カラムクロマトグラフィー(DCM/MeOH、0%〜10%)により、淡黄色の固形粉末として87mgの化合物31を得た。
LC−MS(APCI):m/z=431.1(M+1)+
1H NMR(500MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3、3.65〜3.44(m、4H)、2.46(td、J=9.5、8.6、4.3Hz、1H)、2.11〜1.98(m、6H)
キラル分取クロマトグラフィー用カラムを使用いて、ラセミ化合物31を分離し、目的生成物L−5を得た。
LC−MS(APCI):m/z=431.1(M+1)+
1H NMR(500MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3、3.65〜3.44(m、4H)、2.46(td、J=9.5、8.6、4.3Hz、1H)、2.11〜1.98(m、6H)
化合物30(150mg、0.47mmol)をジクロロメタン25mLに溶解し、CDI(92mg、0.56mmol)を室温で一度に加え、室温で2時間撹拌した。化合物8(62mg、0.68mmol)を一度に加え、室温で30分間攪拌した。水10mLを加え、室温で10分間攪拌した。分取し、水相をジクロロメタン10mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮し、カラムクロマトグラフィー(DCM/MeOH、0%〜10%)により、淡黄色の固形粉末として79mgの化合物32を得た。
LC−MS(APCI):m/z=435.2(M+1)+
1H NMR(500MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、2.46(td、J=9.5、8.6、4.3Hz、1H)、2.11〜1.98(m、6H)
キラル分取クロマトグラフィー用カラムを使用して、ラセミ化合物32を分離し、目的生成物L−6を得た。
LC−MS(APCI):m/z=435.2(M+1)+
1H NMR(500MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、2.46(td、J=9.5、8.6、4.3Hz、1H)、2.11〜1.98(m、6H)
化合物27(339mg、1.21mmol)を重水素化無水メタノール10mLに溶解し、Pd/C(30mg)を加え、室温で一晩水素化した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を濃縮して、無色の油状液として228mgの化合物33を得た。
LC−MS(APCI):m/z=189.7(M+1)+
化合物33(228mg、1.21mmol)および5−クロロ−3−ニトロピラゾロ[1,5−a]ピリミジン(239mg、1.21mmol)を無水エタノール10mLに溶解し、DIPEA(866mg、6.7mmol)を室温で加え、30分間加熱還流した。反応液を濃縮し、カラムクロマトグラフィー(PE/EA、30%〜50%)により、淡黄色の固形粉末として232mgの化合物34を得た。
LC−MS(APCI):m/z=351.2(M+1)+
化合物34(232mg、0.66mmol)を無水メタノール10mLと水3mLに溶解し、還元鉄粉(363mg、6.48mmol)と塩化アンモニウム(70mg、1.32mmol)を室温で加え、2時間加熱還流した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を約3mLまで濃縮し、酢酸エチル10mLおよび水5mLを加え、分取し、水相を酢酸エチル5mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮して、褐色の油状液として208mgの化合物35を得、これをそのまま次のステップに用いた。
化合物35(208mg、0.65mmol)をジクロロメタン20mLに溶解し、CDI(210mg、1.29mmol)を室温で一度に加え、室温で2時間撹拌した。(S)−3−ピロリジノール(113mg、1.29mmol)を一度に加え、室温で30分間撹拌した。水20mLを加え、室温で10分間攪拌した。分取し、水相をジクロロメタン20mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮し、カラムクロマトグラフィー(DCM/MeOH、0%〜10%)により、淡黄色の固形粉末として199mgの化合物36を得た。
LC−MS(APCI):m/z=434.1(M+1)+
1H NMR(500MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3.65〜3.44(m、4H)、2.46(td、J=9.5、8.6、4.3Hz、1H)、2.11〜1.98(m、2H)
キラル分取クロマトグラフィー用カラムを使用して、ラセミ化合物36を分離し、目的生成物L−7を得た。
LC−MS(APCI):m/z=434.1(M+1)+
1H NMR(500MHz、CDCl3)δ 8.23(d、J=4.3Hz、1H)、8.21(s、1H)、8.14(d、J=7.8Hz、1H)、7.05(d、J=25.1Hz、2H)、6.90(s、1H)、6.74(s、1H)、6.05(d、J=7.7Hz、1H)、4.51(m、1H)、3.65〜3.44(m、4H)、2.46(td、J=9.5、8.6、4.3Hz、1H)、2.11〜1.98(m、2H)
(1)キナーゼ阻害作用
化合物の調製:試験化合物をDMSOに溶解して、20mMの母液にした。使用前に、DMSOで化合物を0.1mM(最終濃度の100倍の希釈液)に希釈し、3倍の勾配で11濃度にした。薬物を添加する場合は、緩衝液で最終濃度の4倍の希釈液に希釈した。
ミクロソーム実験:ヒト肝ミクロソーム:0.5mg/mL、Xenotech社;ラット肝ミクロソーム:0.5mg/mL、Xenotech社;コエンザイム(NADPH/NADH):1mM、Sigma Life Science社;塩化マグネシウム:5mM、100mMのリン酸塩緩衝液(pH7.4)。
体重約210gの7〜8週齢の6匹の雄Sprague−Dawleyラットを2群(各群3匹)に分け、それぞれ静脈内または経口で単回用量の化合物(10mg/kg経口)を投与し、その薬物動態の差を比較した。
化合物2(500mg、1.79mmol)を重水素化メタノール10mLに溶解し、Pd/C(50mg)を加えて重水素加圧、室温で一晩水素化した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を濃縮し、無色の油状液として477mg(収率:95.4%)の化合物10を得た。
LC−MS(APCI):m/z=187.1(M+1)+
化合物10(500mg、2.7mmol)および5−クロロ−3−ニトロピラゾロ[1,5−a]ピリミジン(533mg、2.7mmol)を無水エタノール10mLに溶解し、DIPEA(1.74g、13.4mmol)を室温で加え、30分間加熱還流した。反応液を濃縮し、カラムクロマトグラフィー(PE/EA、30%〜50%)により、淡黄色の固形粉末として79mg(収率:84.4%)の化合物11を得た。
LC−MS(APCI):m/z=349.6(M+1)+
化合物11(300mg、0.86mmol)を無水メタノール10mLと水3mLに溶解し、還元鉄粉(485mg、8.66mmol)と塩化アンモニウム(93mg、1.75mmol)を室温で加え、2時間加熱還流した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を約3mLまで濃縮し、酢酸エチル10mLと水5mLを加え、分取し、水相を酢酸エチル5mLで3回抽出し、有機相を合わせて飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、ろ過濃縮して、褐色の油状液として273mgの化合物12を得、これをそのまま次のステップに用いた。
化合物27(339mg、1.21mmol)を無水メタノール10mLに溶解し、Pd/C(30mg)を加え、室温で一晩水素化した。ろ過し、濾渣を酢酸エチル20mLで洗浄し、ろ液を濃縮し、無色の油状液として313mgの化合物28を得た。
LC−MS(APCI):m/z=186.1(M+1)+
Claims (15)
- R5、R6およびR7が水素である、請求項1または2に記載の化合物。
- R8およびR9が重水素である、請求項1〜3のいずれか一項に記載の化合物。
- R10およびR11が重水素である、請求項1〜4のいずれか一項に記載の化合物。
- R12、R13およびR14が重水素である、請求項1〜5のいずれか一項に記載の化合物。
- R1、R2、R3およびR4が重水素である、請求項1〜6のいずれか一項に記載の化合物。
- 薬学的に許容される賦形剤および請求項1〜8のいずれか一項に記載の化合物、またはその薬学的に許容される塩、プロドラッグ、水和物もしくは溶媒化合物、結晶多形、立体異性体もしくは同位体変異体を含む医薬組成物。
- 癌、痛み、炎症、神経変性疾患、またはクルーズ・トリパノソーマ感染症から選択される関連病気を治療するための医薬の製造における、請求項1〜8のいずれか一項に記載の化合物、またはその薬学的に許容される塩、プロドラッグ、水和物もしくは溶媒化合物、結晶多形、立体異性体もしくは同位体変異体、または請求項9に記載の医薬組成物の使用。
- Trkキナーゼ媒介性癌を治療するための医薬の製造における、請求項1〜8のいずれか一項に記載の化合物、またはその薬学的に許容される塩、プロドラッグ、水和物もしくは溶媒化合物、結晶多形、立体異性体もしくは同位体変異体、または請求項9に記載の医薬組成物の使用。
- 前記の癌がTrkAによって媒介される、請求項11に記載の方法。
- 前記の癌がTrkBによって媒介される、請求項11に記載の方法。
- 前記の癌がTrkAおよびTrkBによって媒介される、請求項11に記載の方法。
- 前記の癌がTrkCによって媒介される、請求項11に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711400397 | 2017-12-22 | ||
CN201711400397.3 | 2017-12-22 | ||
PCT/CN2018/121781 WO2019120194A1 (zh) | 2017-12-22 | 2018-12-18 | 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021511291A true JP2021511291A (ja) | 2021-05-06 |
JP7150356B2 JP7150356B2 (ja) | 2022-10-11 |
Family
ID=65613684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020534179A Active JP7150356B2 (ja) | 2017-12-22 | 2018-12-18 | 置換ピラゾロ[1,5-a]ピリミジン化合物並びにその医薬組成物および使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11453672B2 (ja) |
EP (1) | EP3730492A4 (ja) |
JP (1) | JP7150356B2 (ja) |
CN (2) | CN109456331B (ja) |
WO (1) | WO2019120194A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110305138B (zh) * | 2018-03-27 | 2021-04-23 | 海创药业股份有限公司 | 一种治疗癌症的化合物及其用途 |
CN110804059B (zh) * | 2019-09-30 | 2024-03-12 | 郑州泰基鸿诺医药股份有限公司 | 氨基甲酸酯类化合物、药物组合物及其应用 |
CN111302997B (zh) * | 2020-04-15 | 2022-03-29 | 江苏恒沛药物科技有限公司 | “一锅法”制备拉罗替尼中间体的方法 |
CN113307812B (zh) * | 2021-07-01 | 2022-07-22 | 郑州大学第一附属医院 | 广谱肿瘤药拉罗替尼的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012506446A (ja) * | 2008-10-22 | 2012-03-15 | アレイ バイオファーマ、インコーポレイテッド | TRKキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピリミジン化合物 |
JP2015509535A (ja) * | 2012-03-09 | 2015-03-30 | レクシコン ファーマシューティカルズ インコーポレイテッド | ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法 |
JP2017503867A (ja) * | 2014-01-24 | 2017-02-02 | ティーピー・セラピューティクス・インコーポレイテッドTp Therapeutics,Inc. | タンパク質キナーゼのモジュレータとしてのジアリール大環状化合物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100477070B1 (ko) * | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
ATE234299T1 (de) * | 1999-12-03 | 2003-03-15 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel |
TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
AU2006299424A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties |
US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
EP1873157A1 (en) | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
KR102132405B1 (ko) | 2010-05-20 | 2020-07-09 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
RS64122B1 (sr) * | 2014-11-16 | 2023-05-31 | Array Biopharma Inc | Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogensulfata |
WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
KR102599788B1 (ko) | 2015-07-02 | 2023-11-07 | 터닝 포인트 테라퓨틱스, 인크. | 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클 |
US10640495B2 (en) | 2015-07-07 | 2020-05-05 | Shionogi & Co., Ltd. | Heterocycle derivatives having TrkA inhibitory activity |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
CN109467585A (zh) * | 2016-03-11 | 2019-03-15 | 深圳市塔吉瑞生物医药有限公司 | 用于预防或治疗fxr-介导疾病的胆烷酸化合物 |
AU2017246554B2 (en) * | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
-
2018
- 2018-12-18 WO PCT/CN2018/121781 patent/WO2019120194A1/zh unknown
- 2018-12-18 EP EP18891153.1A patent/EP3730492A4/en active Pending
- 2018-12-18 CN CN201811550221.0A patent/CN109456331B/zh active Active
- 2018-12-18 CN CN202010349837.2A patent/CN111362949B/zh active Active
- 2018-12-18 US US16/956,057 patent/US11453672B2/en active Active
- 2018-12-18 JP JP2020534179A patent/JP7150356B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012506446A (ja) * | 2008-10-22 | 2012-03-15 | アレイ バイオファーマ、インコーポレイテッド | TRKキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピリミジン化合物 |
JP2015509535A (ja) * | 2012-03-09 | 2015-03-30 | レクシコン ファーマシューティカルズ インコーポレイテッド | ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法 |
JP2017503867A (ja) * | 2014-01-24 | 2017-02-02 | ティーピー・セラピューティクス・インコーポレイテッドTp Therapeutics,Inc. | タンパク質キナーゼのモジュレータとしてのジアリール大環状化合物 |
Non-Patent Citations (2)
Title |
---|
BUTEAU, K. C.: "DEUTERATED DRUGS: UNEXPECTEDLY NONOBVIOUS?", JOURNAL OF HIGH TECHNOLOGY LAW, vol. 1, JPN5018005307, 2009, pages 22 - 74, ISSN: 0004754068 * |
FOSTER, ALLAN B.: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: Implications for drug design", ADVANCES IN DRUG RESEARCH, vol. 14, JPN5014006660, 1985, pages 1 - 40, XP009086953, ISSN: 0004754067 * |
Also Published As
Publication number | Publication date |
---|---|
CN109456331A (zh) | 2019-03-12 |
CN109456331B (zh) | 2020-06-05 |
JP7150356B2 (ja) | 2022-10-11 |
CN111362949B (zh) | 2021-12-21 |
WO2019120194A1 (zh) | 2019-06-27 |
EP3730492A1 (en) | 2020-10-28 |
EP3730492A4 (en) | 2021-08-11 |
US11453672B2 (en) | 2022-09-27 |
US20210107906A1 (en) | 2021-04-15 |
CN111362949A (zh) | 2020-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7162915B2 (ja) | 置換ピラゾロ[1,5-a]ピリミジン系大環状化合物 | |
ES2744636T3 (es) | Derivados de 4,5,6,7-tetrahidropirazolo[1,5-a]pirazina sustituidos como inhibidores de caseína quinasa 1 D/E | |
JP7150356B2 (ja) | 置換ピラゾロ[1,5-a]ピリミジン化合物並びにその医薬組成物および使用 | |
JP6585158B2 (ja) | ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体 | |
CA3074304A1 (en) | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 | |
ES2770693T3 (es) | Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon | |
JP6267231B2 (ja) | カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール | |
TWI828712B (zh) | 作為trk抑制劑的雜環化合物 | |
JP2013537199A (ja) | Trk阻害薬としてのイミダゾ[1,2]ピリダジン化合物および組成物 | |
AU2018360059A1 (en) | Substituted pyrrolopyrimidine JAK inhibitors and methods of making and using the same | |
EA028175B1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
CA3046864A1 (en) | Cdk4/6 inhibitor | |
WO2019189732A1 (ja) | 光学活性な架橋型環状2級アミン誘導体 | |
IL211277A (en) | Imidazolidine compounds as an androgen receptor modulator | |
JP7432778B2 (ja) | 軟骨形成を誘導するための化合物及び組成物 | |
CN108699080B (zh) | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 | |
JP6586463B2 (ja) | PI3Kβ阻害剤としての複素環連結イミダゾピリダジン誘導体 | |
JP7407309B2 (ja) | Csf-1r阻害剤としての置換{5-メトキシ-6-[(5-メトキシピリジン-2-イル)メトキシ]ピリジン-3-イル}メチル化合物 | |
TW202341983A (zh) | 用於降解突變kras蛋白之化合物及其應用 | |
JP2022548618A (ja) | Mll1阻害剤及び抗癌剤 | |
CN117659049A (zh) | 取代桥环类抑制剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201027 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201027 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220719 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220906 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220920 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7150356 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |